Free Cash Flow per Share: A measure of financial performance calculated as operating cash flow minus capital expenditures, expressed on a per share basis. Calculated as: Free Cash Flow / Weighted Average Shares Outstanding (Diluted)
Keros Therapeutics, Inc. (KROS) had Free Cash Flow per Share of $-1.22 for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
-- |
|
$-28.71M |
|
-- |
|
-- |
|
$30.94M |
|
$-30.94M |
|
$2.23M |
|
$-28.71M |
|
$-28.71M |
|
$-28.71M |
|
$-28.71M |
|
$-28.71M |
|
$-28.71M |
|
$-30.94M |
|
$-30.54M |
|
19.80M |
|
19.80M |
|
$-1.45 |
|
$-1.45 |
|
| Balance Sheet Financials | |
$266.88M |
|
$3.71M |
|
$20.72M |
|
$287.60M |
|
$12.15M |
|
-- |
|
$13.13M |
|
$25.28M |
|
$262.32M |
|
$262.32M |
|
$262.32M |
|
19.83M |
|
| Cash Flow Statement Financials | |
$-23.95M |
|
$-0.23M |
|
$-5.63M |
|
$288.86M |
|
$259.06M |
|
$-29.81M |
|
$11.58M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
21.96 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-24.18M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-10.94% |
|
-10.94% |
|
-9.98% |
|
-10.94% |
|
$13.23 |
|
|
Free Cash Flow per Share |
$-1.22 |
$-1.21 |
|